These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 23395788)
1. [Pleiotropic effects of incretins and antidiabetic drugs with incretine mechanism]. Winkler G Orv Hetil; 2013 Feb; 154(7):248-55. PubMed ID: 23395788 [TBL] [Abstract][Full Text] [Related]
2. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Chrysant SG; Chrysant GS Am J Cardiol; 2012 Jun; 109(11):1681-5. PubMed ID: 22425330 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Thornberry NA; Gallwitz B Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065 [TBL] [Abstract][Full Text] [Related]
4. Renoprotective effects of incretin-based drugs: A novel pleiotropic effect of dipeptidyl peptidase-4 inhibitor. Kodera R; Shikata K J Diabetes Investig; 2016 Jan; 7(1):29-31. PubMed ID: 26816598 [TBL] [Abstract][Full Text] [Related]
5. [The physiology of incretins]. Winkler G Orv Hetil; 2011 Nov; 152(48):1922-30. PubMed ID: 22167829 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular protective properties of incretin-based therapies in type 2 diabetes. Simsek S; de Galan BE Curr Opin Lipidol; 2012 Dec; 23(6):540-7. PubMed ID: 23160401 [TBL] [Abstract][Full Text] [Related]
7. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. Boland CL; Degeeter M; Nuzum DS; Tzefos M Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular effects of incretins in diabetes. Advani A; Bugyei-Twum A; Connelly KA Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557 [TBL] [Abstract][Full Text] [Related]
9. [Innovations in the treatment of type 2 diabetes mellitus: use of incretins]. Dedov II; Shestakova MV; Sukhareva OIu Ter Arkh; 2010; 82(10):5-10. PubMed ID: 21341455 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. Balakumar P; Dhanaraj SA Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531 [TBL] [Abstract][Full Text] [Related]
11. The role of incretin-based therapies in the management of type 2 diabetes. Bandyopadhyay P Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733 [TBL] [Abstract][Full Text] [Related]
12. [The value of incretin based therapies]. Gallwitz B Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931 [No Abstract] [Full Text] [Related]
13. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Jellinger PS Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084 [TBL] [Abstract][Full Text] [Related]